Radiographic Progression-Free Survival and Overall Survival Correlation in TALAPRO-2 - Neeraj Agarwal
Neeraj Agarwal
Neeraj Agarwal presents a correlation analysis from TALAPRO-2 examining whether radiographic progression-free survival predicts overall survival in the phase 3 trial of enzalutamide plus talazoparib in first-line mCRPC.
Lutetium-177 PSMA-617 Therapy Across the Prostate Cancer Spectrum: Mechanism, Formulation, and Future Directions - Phillip Koo
Phillip Koo
Phillip Koo explains the mechanistic components of radioligand therapy, describing how the isotope, chelator, and targeting agent each independently influence biodistribution and efficacy.
